This inventor holds 1 USPTO granted patent and 6 published patent applications, plus 2 CIPO patents. Top assignee: Takeda Pharmaceutical Company Limited. Active years: 2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2024
Title: Abhijit Suresh Bhat: Innovator in GIP Receptor Agonist Peptide Compounds
Introduction
Abhijit Suresh Bhat is a notable inventor based in Cambridge, MA (US). He has made significant contributions to the field of medicinal chemistry, particularly in the development of peptide compounds that target GIP receptors. His work is crucial for advancing treatments for various metabolic conditions.
Latest Patents
Abhijit holds a patent for GIP receptor agonist peptide compounds and their uses. The patent describes peptide compounds that activate GIP receptors, which can be utilized as a medicament for the treatment and prevention of diabetes, obesity, and related conditions. The specific peptide sequence is represented by the formula (I), which is designed to enhance therapeutic efficacy.
Career Highlights
Abhijit is currently employed at Takeda Pharmaceutical Company Limited, where he continues to innovate in the field of pharmaceuticals. His research focuses on developing new treatments that can improve patient outcomes in metabolic diseases.
Collaborations
He collaborates with esteemed colleagues such as Hiroshi Imoto and Mari Adachi, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
Abhijit Suresh Bhat's work in GIP receptor agonist peptide compounds exemplifies the impact of innovative research in medicine. His contributions are paving the way for new therapeutic options in the treatment of diabetes and obesity.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile